Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients

Diabetologia

Volumn 48, Issue 11, 2005, Pages 2241-2247

  Rossing, K ^a   Christensen, P K ^a   Hovind, P ^a   Parving, H H ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Albuminuria; Antihypertensive treatment; Blood pressure; Diabetic nephropathy; End stage renal disease; Mortality; Nephrotic range albuminuria; Type 2 diabetes

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRIORITY JOURNAL; REGRESSION ANALYSIS; RELAPSE; REMISSION; RISK REDUCTION; SAMPLE SIZE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE;

EID: 27744490190     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1937-6     Document Type: Article

References (23)

1. Kussman MJ, Goldstein H-H, Gleason RE (1976) The clinical course of diabetic nephropathy. JAMA 236:1861-1863
2. Parving H-H, Mauer M, Ritz E (2004) Diabetic nephropathy. In: Brenner BM (ed) Brenner and Rector's the Kidney. WB Saunders, Philadelphia, pp 1777-1818
3. Watkins PJ, Blainey JD, Brewer DB et al (1972) The natural history of diabetic renal disease. A follow-up study of series of renal biopsies. Q J Med 41:437-456
4. Rossing P, Hommel E, Smidt UM, Parving H-H (1994) Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516
5. de Zeeuw D, Remuzzi G, Parving H-H et al (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65:2309-2320
6. de Zeeuw D, Remuzzi G, Parving H-H et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921-927
7. Mogensen CE (1976) Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 36:383-388
8. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR (1981) A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20:457-461
9. Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
10. Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
11. Herbert LA, Bain RP, Verme D et al (1994) Remission of nephrotic-range proteinuria in type I diabetes. Kidney Int 46:1688-1693
12. Hovind P, Rossing P, Tarnow L, Toft H, Parving J, Parving H-H (2001) Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 24:1972-1977
13. Hovind P, Tarnow L, Rossing P, Carstensen B, Parving H-H (2004) Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int 66:1180-1186
14. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving H-H (2004) Progression of nephropathy in type 2 diabetic patients. Kidney Int 66:1596-1605
15. American Diabetes Association (1993) Treatment of hypertension in diabetes. Diabetes Care 16:1394-1401
16. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878
17. Bröchner-Mortensen J, Rödbro P (1976) Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35-45
18. Miles DW, Mogensen CE, Gundersen HJG (1970) Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest 26:5-11
19. Feldt-Rasmussen B, Dinesen B, Deckert M (1985) Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539-544
20. Lewis E, Hunsicker L, Bain R, Rhode R (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462
21. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H (2001) Progression of diabetic nephropathy. Kidney Int 59:702-709
22. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving H-H (2003) Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 14:2843-2850
23. Pladevall M (2004) Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 27:2800-2805